Translate page

English English
en Englishbg Bulgarianzh-CN Chinese (Simplified)hr Croatiancs Czechda Danishnl Dutchfi Finnishfr Frenchde Germanel Greekiw Hebrewhi Hindiid Indonesianit Italianja Japaneseko Koreanmk Macedonianpl Polishpt Portuguesero Romanianru Russiansr Serbiansk Slovaksl Slovenianes Spanishsv Swedishth Thaitr Turkishvi Vietnamese

News

Catch up with the iCMLf in our June 2022 Newsletter

June 2022 - It’s our pleasure to bring you the latest iCMLf Newsletter for June 2022. Read about our most recent achievements, including those in our Global Alliances.

Contents Overview:

  • iCMLf Global Alliances - driving international research for CML
  • The iCMLf CANDID (Cml AND covID) Study - an analysis of COVID-19 In Patients With Chronic Myeloid Leukemia
  • The 2022 iCMLf, Goldman and Rowley Prize Recipients
  • A feature from Jane Apperley – celebrating 40-years in medicine
  • A feature from Ravi Bhatia and his investigation - The seed and the soil – the leukemia stem cell in its niche and the quest for cure
  • A feature from Sabira Kurtovic - how limited limited access to treatment has created lessons that are helping shape future approaches for CML
  • A iCMLf Knowledge Centre Update - a place for the CML community of physicians and scientists, to share cutting edge, best practice CML management.

iCMLf COVID-19 Hub - Updated statement on COVID-19 vaccines for people with CML

COVID 19 Hub screen shotMay 2022 - Our continuous commitment as a Foundation is to support the CML community with reliable up to date information about COVID-19 and CML – even now, in the third year of the pandemic.

Questions about CML management during the COVID-19 pandemic remain highly relevant for clinical practice. In particular, whether COVID-19 vaccines are recommended and effective for people with CML.

To provide you with the best possible support, the iCMLf continues to update our COVID-19 Hub with CML specific information on COVID-19. We are also sharing an updated statement on COVID-19 vaccines for people with CML. You can read the full statement below:

We are at EHA 2022!! – Overview of CML sessions available

Logo EHA 2022

It's great to be back in person at the 2022 Congress of the European Hematology Association. The congress is being held as a hybrid meeting in Vienna and online from June 9-17, 2022:

  • June 9-12: Live streamed program                                   
  • June 15-17: Virtual thematic days

To help you plan your CML meeting schedule at EHA we have compiled a list of CML related sessions for your convenience.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        You can look forward to an exciting scientific program and a highlight from the iCMLf: A first sub-analysis of the iCMLf CML and COVID-19 CANDID data will be presented as a clinical poster during EHA.

We are looking forward to seeing you live in Vienna or online!

iCMLf Knowledge Centre - Management Practicalities

icmlf knowledge center bannerMay 2022 - We are pleased to announce that the latest module of the iCMLf Knowledge Centre – ‘Management Practicalities’ – will be rolled out in two tranches with the first set of presentations now available.

Module 5 is a series of talks that will feature various topics on the practical management of CML to help you in your clinical practice.

Topics include; managing intolerances and relevant comorbidities, TKI interactions and adverse events. This highly practical module is chaired by Professor Giuseppe Saglio (Italy) and Professor Mohamed Yassin (Qatar).

Update on COVID-19 and CML in Portuguese on May 31st at 8.30 Brazilian Time / 13.30 CET

Flagge BrasilienMay 2022 - Questions about CML management during the COVID-19 pandemic remain highly relevant for clinical practice. To provide physicians treating CML around the world with best possible support, we are hosting expert talks on CML and COVID-19 management in French, Portuguese, Spanish and Russian.

If you speak Portuguese, join us for the live expert talk in Portuguese on May 31st at 8.30 AM Brazilian Time with Dr Katia Pagnano from Brazil. You will learn how to best treat your patients with CML and COVID-19 and get the latest updates on COVID-19 vaccines for patients with CML.

As a reminder the presentation on COVID-19 and CML in French is available here

iCMLf CANDID data - Sub-analysis of patients with COVID-19 and CML in TFR accepted for EHA

CoronavirusApril 2022 - We are delighted to share that a first sub-analysis of the iCMLf CML and COVID-19 CANDID data has been accepted as a clinical poster presentation for the EHA 2022 Congress in June:

COVID-19 in patients with chronic myeloid leukemia in treatment-free remission:
Disease-severity and impact on TFR status (Saußele S et al. EHA 2022 abstract no. 1886)

The sub-analysis of the CANDID study aimed to evaluate the outcome of SARS-CoV-2 infection in CML patients in treatment-free remission and assessed any impact on maintenance of TFR. Additional information were collected for this analysis including: molecular remission status before, during and after COVID-19 infection.

We look forward to seeing you at EHA and sharing more details.